| 750518 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P09.05 Plasma CD27, a surrogate of intratumoral CD27-CD70 interaction, correlates with immunotherapy resistance in renal cancer |
2021-10-01 |
10.1136/jitc-2021-itoc8.55 |
Benhamouda N, Sam I, Epaillard N, Gey A, Saldmann A, Pineau J, Hasan M, Verkarre V, Libri V, Mella S, Granier C, Broudin C, Ravel P, Jabla B, Chaput N, Albiges L, Vano Y, Adotevi O, Oudard S, Tartour E |
| 750517 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P08.02 CCR2/CCR5 dual-antagonist ‘licenses’ the radiation-induced effector T-cell infiltration in the anti-PD-1 antibody-treated pancreatic adenocarcinoma |
2021-10-01 |
10.1136/jitc-2021-itoc8.46 |
Wang J, Tun Saung M, Fujiwara K, Niu N, Narang A, He J, Zheng L |
| 750516 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
10.03 Interleukin-22 regulates anti-tumor immunity in mouse models of lung and breast carcinoma |
2021-10-01 |
10.1136/jitc-2021-itoc8.3 |
Briukhovetska D, Suarez-Gosalvez J, Schübel M, Markota A, Jobst J, Dörr J, Märkl F, Schwerdtfeger M, Öner A, Seifert M, Gottschlich A, Endres S, Kobold S |
| 750515 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P09.03 Hyaluronic acid as a new immunologic adjuvant in cancer: design of effective preventive and therapeutic vaccination strategies for HER2/neu-positive breast tumors |
2021-10-01 |
10.1136/jitc-2021-itoc8.53 |
Carpanese D, Montagner I, Dalla Pietà A, Rossi V, Penna A, Zuccolotto G, Pasut G, Grigoletto A, Rosato A |
| 750514 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P02.11 TREM1 agonist PY159 promotes myeloid cell reprogramming and unleashes anti-tumor immunity |
2021-10-01 |
10.1136/jitc-2021-itoc8.23 |
Juric V, Mayes E, Binnewies M, Canaday P, Lee T, Dash S, Pollack JL, Rudolph J, Huang V, Du X, Jahchan N, Ramoth AJ, Mankikar S, Norng M, Santamaria C, Baker KP, Liang L |
| 750513 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P09.06 Investigating various patient parameters as prognostic markers for patients with advance stage nasopharyngeal carcinoma undergoing induction chemotherapy followed by Epstein-Barr virus cytotoxic T-lymphocyte immunotherapy |
2021-10-01 |
10.1136/jitc-2021-itoc8.56 |
Chu A, Han S, Toh H |
| 750512 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
P01.02 TLR-mediated suppression of the CCL22-CCR4 axis as a new target for tumor immunotherapy |
2021-10-01 |
10.1136/jitc-2021-itoc8.6 |
Grün J, Piseddu I, Perleberg C, Röhrle N, Endres S, Anz D |
| 750511 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei |
2021-10-01 |
10.1136/jitc-2021-003109 |
Flatmark Kjersti, Torgunrud Annette, Fleten Karianne G, Davidson Ben, Juul Hedvig V, Mensali Nadia, Lund-Andersen Christin, Inderberg Else Marit |
| 750510 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
Treatment of recurrent mucosal melanoma of the oral cavity with topical imiquimod and pembrolizumab achieves complete histopathologic remission |
2021-10-01 |
10.1136/jitc-2020-001219 |
Satish Tejus, Khan Shaheer, Levin Matt, Carvajal Richard, Yoon Angela J |
| 750509 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma |
2021-10-01 |
10.1136/jitc-2021-003288 |
Miyamoto Yosuke, Kozuki Toshiyuki, Aoe Keisuke, Wada Sae, Harada Daijiro, Yoshida Michihiro, Sakurai Jun, Hotta Katsuyuki, Fujimoto Nobukazu |
